Streptozotocin-Induced Diabetes

Description

The Streptozotocin diabetes model is a well published diabetes model in the field that is frequently used in preclinical drug development. Streptozotocin is an antibiotic derived from Streptomyces achromogenes that preferentially targets and destroys insulin-secreting pancreatic β cells and can be used to induce a hyperglycemic state in rodents. These models are characterized by altered blood glucose and insulin levels and can be used to assess disease pathology or to screen potential therapeutic compounds.

Model Systems
  • C57Bl/6 Mice
  • Fisher Rat
Standard Readouts
  • Percent weight change
  • Blood glucose
  • Blood insulin
Additional Readouts
  • Wound healing
  • Survival
  • Histopathology and/or IHC analyses
  • Multiplex/cytokine analysis
  • Peripheral lymphoid organ immunophenotyping
  • Custom assays
Representative DataClick Image to Enlarge
Percent Weight Change in a Murine Model of Streptozotocin-Induced Type I Diabetes

Streptozotocin-induced animals are weighed daily, and percent body weight change relative to Day 0 is calculated. The AUC is calculated to compare groups and is shown in the inset. (****p<0.0001).

Blood Glucose Levels in a Murine Model of Streptozotocin-Induced Type I Diabetes

Blood glucose levels are monitored using a blood glucose reader. The AUC is calculated to compare groups and is shown in the inset. (*p<0.05; ****p<0.0001).

Day 14 Blood Glucose and Blood Insulin Levels in a Murine Model of Streptozotocin-Induced Type I Diabetes

Day 14 Blood glucose and blood insulin levels were measured via glucose monitor and ELISA, respectively. (****p<0.0001).

Daniel Lichtman

Managing Partner